Skip to main content
Erschienen in: Wiener klinische Wochenschrift 17-18/2017

03.08.2017 | short report

Dalbavancin for outpatient parenteral antimicrobial therapy of skin and soft tissue infections in a returning traveller

Proposal for novel treatment indications

verfasst von: Johannes Mischlinger, MD, MSc, DTM&H, Heimo Lagler, Nicole Harrison, Michael Ramharter

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 17-18/2017

Einloggen, um Zugang zu erhalten

Summary

Skin and soft tissue infections (SSTIs) are among the most common health problems in travellers returning from tropical and subtropical countries. Importantly, the prevalence of Staphylococcus aureus, the most common pathogen for purulent SSTIs, with specific drug resistance, such as methicillin resistant Staphylococcus aureus (MRSA) and those expressing virulence genes, such as Panton-Valentine-leukocidin is higher in tropical regions than in most high resource settings. This poses challenges for the empirical antimicrobial treatment of SSTIs in returning travellers. This short report describes a patient with a recent travel history to Hong Kong, Singapore and the Philippines who presented with multiple mosquito bites on both upper extremities and secondary bacterial superinfection. He had previously been prescribed oral beta-lactam antimicrobial therapy but lacked adherence to this treatment. Based on the risk for MRSA infection and problems with treatment adherence to oral therapy an outpatient parenteral antimicrobial therapy with dalbavancin was administered on days 0 and 7. Microbiological culture confirmed presence of MRSA and clinical follow-up demonstrated complete remission of the SSTI within 2 weeks. Dalbavancin is a promising treatment option for empirical parenteral treatment of SSTIs in returning travellers, a population at high risk for beta-lactam resistant S. aureus skin infections.
Literatur
1.
Zurück zum Zitat Hochedez P, Canestri A, Lecso M, Valin N, Bricaire F, Caumes E. Skin and soft tissue infections in returning travelers. Am J Trop Med Hyg. 2009;80(3):431–4.PubMed Hochedez P, Canestri A, Lecso M, Valin N, Bricaire F, Caumes E. Skin and soft tissue infections in returning travelers. Am J Trop Med Hyg. 2009;80(3):431–4.PubMed
2.
Zurück zum Zitat Adler A, Temper V, Block CS, Abramson N, Moses AE. Panton-valentine Leukocidin-producing staphylococcus aureus. Emerging Infect Dis. 2006;12(11):1789–90.CrossRefPubMedPubMedCentral Adler A, Temper V, Block CS, Abramson N, Moses AE. Panton-valentine Leukocidin-producing staphylococcus aureus. Emerging Infect Dis. 2006;12(11):1789–90.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Stenhem M, Örtqvist Å, Ringberg H, Larsson L, Olsson-Liljequist B, Hæggman S, et al. Imported Methicillin-Resistant Staphylococcus aureus, Sweden. Emerging Infect Dis. 2010;16(2):189–96.CrossRefPubMedPubMedCentral Stenhem M, Örtqvist Å, Ringberg H, Larsson L, Olsson-Liljequist B, Hæggman S, et al. Imported Methicillin-Resistant Staphylococcus aureus, Sweden. Emerging Infect Dis. 2010;16(2):189–96.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Zanger P, Nurjadi D, Schleucher R, Scherbaum H, Wolz C, Kremsner PG, et al. Import and spread of Panton-valentine Leukocidin-positive staphylococcus aureus through nasal carriage and skin infections in travelers returning from the tropics and subtropics. Clin Infect Dis. 2012;54(4):483–92.CrossRefPubMed Zanger P, Nurjadi D, Schleucher R, Scherbaum H, Wolz C, Kremsner PG, et al. Import and spread of Panton-valentine Leukocidin-positive staphylococcus aureus through nasal carriage and skin infections in travelers returning from the tropics and subtropics. Clin Infect Dis. 2012;54(4):483–92.CrossRefPubMed
5.
Zurück zum Zitat Zervos M. Treatment options for uncomplicated community-acquired skin and soft tissue infections caused by methicillin-resistant staphylococcus aureus: oral antimicrobial agents. Surg Infect (Larchmt). 2008;9(Suppl 1):s29–s34.CrossRef Zervos M. Treatment options for uncomplicated community-acquired skin and soft tissue infections caused by methicillin-resistant staphylococcus aureus: oral antimicrobial agents. Surg Infect (Larchmt). 2008;9(Suppl 1):s29–s34.CrossRef
6.
Zurück zum Zitat Adegnika AA, Breitling LP, Agnandji ST, Chai SK, Schutte D, Oyakhirome S, et al. Effectiveness of quinine monotherapy for the treatment of Plasmodium falciparum infection in pregnant women in Lambarene, Gabon. Am J Trop Med Hyg. 2005;73(2):263–6.PubMed Adegnika AA, Breitling LP, Agnandji ST, Chai SK, Schutte D, Oyakhirome S, et al. Effectiveness of quinine monotherapy for the treatment of Plasmodium falciparum infection in pregnant women in Lambarene, Gabon. Am J Trop Med Hyg. 2005;73(2):263–6.PubMed
7.
Zurück zum Zitat Mischlinger J, Agnandji ST, Ramharter M. Single dose treatment of malaria – current status and perspectives. Expert Rev Anti Infect Ther. 2016;14(7):669–78.CrossRefPubMed Mischlinger J, Agnandji ST, Ramharter M. Single dose treatment of malaria – current status and perspectives. Expert Rev Anti Infect Ther. 2016;14(7):669–78.CrossRefPubMed
8.
Zurück zum Zitat The malERA Consultative Group on Health Systems and Operational Research. A research agenda for malaria eradication: health systems and operational research. PLoS Med. 2011;8(1):e1000397.CrossRefPubMedCentral The malERA Consultative Group on Health Systems and Operational Research. A research agenda for malaria eradication: health systems and operational research. PLoS Med. 2011;8(1):e1000397.CrossRefPubMedCentral
9.
Zurück zum Zitat Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother. 2009;53(3):1260–3.CrossRefPubMedPubMedCentral Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother. 2009;53(3):1260–3.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008;46(4):577–83.CrossRefPubMed Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008;46(4):577–83.CrossRefPubMed
11.
Zurück zum Zitat Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–79.CrossRefPubMed Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–79.CrossRefPubMed
12.
Zurück zum Zitat Eckmann C, Lawson W, Nathwani D, Solem CT, Stephens JM, Macahilig C, et al. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents. 2014;44(1):56–64.CrossRefPubMed Eckmann C, Lawson W, Nathwani D, Solem CT, Stephens JM, Macahilig C, et al. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents. 2014;44(1):56–64.CrossRefPubMed
13.
Zurück zum Zitat Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005;55(Suppl 2):ii15–ii20.PubMed Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005;55(Suppl 2):ii15–ii20.PubMed
14.
Zurück zum Zitat Scott LJ. Dalbavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75(11):1281–91.CrossRefPubMed Scott LJ. Dalbavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75(11):1281–91.CrossRefPubMed
15.
Zurück zum Zitat Candel FJ, Julian-Jimenez A, Gonzalez-Del Castillo J. Current status in outpatient parenteral antimicrobial therapy: a practical view. Rev Esp Quimioter. 2016;29(2):55–68.PubMed Candel FJ, Julian-Jimenez A, Gonzalez-Del Castillo J. Current status in outpatient parenteral antimicrobial therapy: a practical view. Rev Esp Quimioter. 2016;29(2):55–68.PubMed
16.
Zurück zum Zitat Seaton RA, Barr DA. Outpatient parenteral antibiotic therapy: principles and practice. Eur J Intern Med. 2013;24(7):617–23.CrossRefPubMed Seaton RA, Barr DA. Outpatient parenteral antibiotic therapy: principles and practice. Eur J Intern Med. 2013;24(7):617–23.CrossRefPubMed
17.
Zurück zum Zitat Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr.. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–61.CrossRefPubMedPubMedCentral Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr.. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–61.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol. 2007;8(5):259–70.CrossRefPubMed Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol. 2007;8(5):259–70.CrossRefPubMed
19.
Zurück zum Zitat Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29(5):1128–32.CrossRefPubMed Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29(5):1128–32.CrossRefPubMed
20.
Zurück zum Zitat Pechere JC, Hughes D, Kardas P, Cornaglia G. Non-compliance with antibiotic therapy for acute community infections: a global survey. Int J Antimicrob Agents. 2007;29(3):245–53.CrossRefPubMed Pechere JC, Hughes D, Kardas P, Cornaglia G. Non-compliance with antibiotic therapy for acute community infections: a global survey. Int J Antimicrob Agents. 2007;29(3):245–53.CrossRefPubMed
21.
Zurück zum Zitat Fernandes M, Leite A, Basto M, Nobre MA, Vieira N, Fernandes R, et al. Non-adherence to antibiotic therapy in patients visiting community pharmacies. Int J Clin Pharm. 2014;36(1):86–91.CrossRefPubMed Fernandes M, Leite A, Basto M, Nobre MA, Vieira N, Fernandes R, et al. Non-adherence to antibiotic therapy in patients visiting community pharmacies. Int J Clin Pharm. 2014;36(1):86–91.CrossRefPubMed
22.
Zurück zum Zitat Yamamoto Y, Kadota J, Watanabe A, Yamanaka N, Tateda K, Mikamo H, et al. Compliance with oral antibiotic regimens and associated factors in Japan: compliance survey of multiple oral antibiotics (COSMOS). Scand J Infect Dis. 2012;44(2):93–9.CrossRefPubMed Yamamoto Y, Kadota J, Watanabe A, Yamanaka N, Tateda K, Mikamo H, et al. Compliance with oral antibiotic regimens and associated factors in Japan: compliance survey of multiple oral antibiotics (COSMOS). Scand J Infect Dis. 2012;44(2):93–9.CrossRefPubMed
23.
Zurück zum Zitat Galactionova K, Tediosi F, de Savigny D, Smith T, Tanner M. Effective coverage and systems effectiveness for malaria case management in Sub-Saharan African countries. PLOS ONE. 2015;10(5):e0127818.CrossRefPubMedPubMedCentral Galactionova K, Tediosi F, de Savigny D, Smith T, Tanner M. Effective coverage and systems effectiveness for malaria case management in Sub-Saharan African countries. PLOS ONE. 2015;10(5):e0127818.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Hill J. Adherence with drug therapy in the rheumatic diseases part two: measuring and improving adherence. Musculoskeletal Care. 2005;3(3):143–56.CrossRefPubMed Hill J. Adherence with drug therapy in the rheumatic diseases part two: measuring and improving adherence. Musculoskeletal Care. 2005;3(3):143–56.CrossRefPubMed
25.
Zurück zum Zitat Sondo P, Derra K, Diallo-Nakanabo S, Tarnagda Z, Zampa O, Kazienga A, et al. Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malar J. 2015;14:325.CrossRefPubMedPubMedCentral Sondo P, Derra K, Diallo-Nakanabo S, Tarnagda Z, Zampa O, Kazienga A, et al. Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malar J. 2015;14:325.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Lotsch F, Auer-Hackenberg L, Groger M, Rehman K, Morrison V, Holmes E, et al. Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria. Wien Klin Wochenschr. 2015;127(9–10):379–84.CrossRefPubMed Lotsch F, Auer-Hackenberg L, Groger M, Rehman K, Morrison V, Holmes E, et al. Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria. Wien Klin Wochenschr. 2015;127(9–10):379–84.CrossRefPubMed
27.
Zurück zum Zitat World Health Organisation. Guidelines for the treatment of malaria, 3rd ed. Geneva: WHO; 2015. World Health Organisation. Guidelines for the treatment of malaria, 3rd ed. Geneva: WHO; 2015.
28.
Zurück zum Zitat Kremsner PG, Radloff P, Metzger W, Wildling E, Mordmuller B, Philipps J, et al. Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob Agents Chemother. 1995;39(7):1603–5.CrossRefPubMedPubMedCentral Kremsner PG, Radloff P, Metzger W, Wildling E, Mordmuller B, Philipps J, et al. Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob Agents Chemother. 1995;39(7):1603–5.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Ramdeen S, Boucher HW. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2015;16(13):2073–81.CrossRefPubMedPubMedCentral Ramdeen S, Boucher HW. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2015;16(13):2073–81.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931–40.CrossRefPubMedPubMedCentral Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931–40.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly Dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–51.CrossRefPubMed Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly Dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–51.CrossRefPubMed
Metadaten
Titel
Dalbavancin for outpatient parenteral antimicrobial therapy of skin and soft tissue infections in a returning traveller
Proposal for novel treatment indications
verfasst von
Johannes Mischlinger, MD, MSc, DTM&H
Heimo Lagler
Nicole Harrison
Michael Ramharter
Publikationsdatum
03.08.2017
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 17-18/2017
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-017-1243-6

Weitere Artikel der Ausgabe 17-18/2017

Wiener klinische Wochenschrift 17-18/2017 Zur Ausgabe

MUW researcher of the month

MUW researcher of the month